Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prostaglandin Inhibition and Programmed Cell Death Protein 1 (PD-1)/Cytotoxic T-lymphocyte-Associated Protein 4 (CTLA4) Blockade in Melanoma

NCT03396952 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT03396952
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03396952 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prostaglandin Inhibition and Programmed Cell Death Protein 1 (PD-1)/Cytotoxic T-lymphocyte-Associated Protein 4 (CTLA4) Blockade in Melanoma
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Completed
Start date
April 19, 2018
Completion date
June 30, 2022
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage iii cutaneous melanoma, stage iiia cutaneous melanoma, stage iiib cutaneous melanoma, stage iiic cutaneous melanoma, stage iv cutaneous melanoma